The Complete Hard Capsule Compendium: Technology, Formulation, and Advanced Applications

17 November, 2025
Contents:
    Add a header to start generating the table of contents

    I. Introduction to Hard Capsules: Anatomy, Materials, and Basics



    A. Definition and Construction: Body-Lid System

     

    A hard capsule, in its fundamental form, is a solid dosage form intended for oral administration. Its design is based on a system of two prefabricated, cylindrical components: a longer "body" and a shorter "cap" that precisely slides over the body, enclosing the contents.1

    Historically, hard capsules are, next to tablets, the key oral solid dosage form (OSD) that dominates market pharmaceutical.2 Their primary function is to deliver a precisely measured dose of the active ingredient (API). At the same time, they play a key supportive role for the patient: they effectively mask the unpleasant taste and odor of the medicinal substances and, thanks to their smooth and streamlined surface, significantly facilitate swallowing.1

     

    B. Size Standardization: Overview (000 to 5)

     

    The key aspect that enabled the global development of technology hard capsules, is their strict dimensional standardization. Industrial production is based on a unified system of sizes, classified numerically from the largest, designated as #000 (pronounced "triple zero"), through #00, #0, #1, #2, #3, #4, down to the smallest size #5.3

    This fundamental standardization is not a new invention; it was introduced as early as 1877 by F.A. Hubel.4 This standardization of dimensions directly translates to the volume that can be filled into a capsule. For example, while size #000 holds approximately 1.37 ml, size #0 (often used) holds 0.68 ml, and the smallest size #5 holds only 0.13 ml.3 Selecting the appropriate size is therefore one of the first and critical decisions in the formulation process, depending on the target API dose and the physical properties (e.g., bulk density) of the powder mixture used.

    This early standardization4 was not just a convenience; it became a fundamental prerequisite for the development of the entire automated capsule industry. Modern, high-performance filling machines (capsule filling machines), capable of processing thousands of units per minute5, rely on extremely precise mechanics and interchangeable format parts (segments, dosing disks).6 Without strict, global standardization of sizes3 by various manufacturers of empty capsules, the design of universal filling machines would have been impossible.

     

    C. Evolution of Shell Materials: From Gelatin to Plant Polymers

     

    The original hard capsule technology, patented in 1846 by J.C. Lehuby, was based on glycerogelatin.4 For over a century, gelatin1 remained the undisputed “gold standard” in capsule production.

    However, modern drug formulation technology, driven by both new formulation challenges and growing market demands, has significantly expanded the range of available materials. In addition to traditional gelatin, plant-derived polymers now play a key role. The most important of these is hydroxypropylmethylcellulose (HPMC) 2, which forms the basis of vegetarian capsules. Pullulan 8 is also gaining importance, and materials such as starch and polyvinyl alcohol (PVA) are also appearing in niche applications. 8

    In this context, it is important to emphasize that hard capsules are not simply a simple alternative to tablets. They constitute a distinct technological platform for solving specific formulation challenges that traditional tableting cannot effectively address.2 Encapsulation allows for the flexible delivery of substances in their original form, such as powders, granulates, pellets, minitablets, and even liquids or pastes.11 This allows for the bypassing of complex and often problematic stages of testing compressibility, granulation, and the effect of compression forces on the API, which are inherent to the tableting process. This makes capsules the preferred choice for many new, potent, or sensitive active substances.2

     

    II. Comparative Analysis of Capsule Shell Materials

     

    Selecting the capsule shell material has ceased to be a passive decision about the "container." It has become one of the first and most important active steps in formulation design. The shell material is now considered a functional excipient that directly impacts the API's stability, dissolution profile, and ultimate market acceptance.

     

    A. Gelatin: The Gold Standard and Its Limitations

     

    Gelatin, as a product of animal origin2, has been the industry standard for decades due to its excellent, flexible film-forming properties and rapid and predictable solubility in body fluids at body temperature.13 Despite its dominant position, it has fundamental limitations that have become the driving force behind the search for alternatives:

    1. Moisture Sensitivity: Gelatin is a hygroscopic material. Its equilibrium moisture content is high, typically 13–16%.14 This makes it an unsuitable material of choice for APIs that are highly hygroscopic (which can draw water from the shell, leading to embrittlement) or sensitive to hydrolysis (where moisture from the shell can initiate API degradation).2

    2. Cross-linking Risk: Gelatin is susceptible to cross-linking reactions, particularly in the presence of aldehydes (e.g., from excipient degradation) or as a result of aging under stressful conditions.2 This process leads to the formation of an insoluble polymer "skin" that drastically slows or completely blocks the dissolution of the coating. This is a critically dangerous phenomenon, as it prevents the release of the drug in the body, directly impacting the bioavailability and efficacy of the therapy.

    3. Physical Instability: Gelatin shells become brittle and fragile in low humidity conditions, while becoming soft and sticky in high humidity.16 This requires strict control of storage and transportation conditions.2

    4. Market Restrictions: The animal origin of gelatin makes it unacceptable to a growing group of consumers seeking vegan, vegetarian products and to patients requiring Halal or Kosher certification.2

     

    B. Hypromellose (HPMC): A Solution for Sensitive APIs and Market Requirements

     

    Hypromellose (hydroxypropyl methylcellulose) is a semi-synthetic polymer of plant origin, obtained from cellulose (e.g., wood fibers).2 It is currently the most important alternative to gelatin, known under trade names such as Vcaps®.9 Its advantages address the limitations of gelatin almost point by point:

    1. Low and Stable Moisture: The water content of HPMC is much lower, typically ranging from 3% to 8%14 or 4–6%.15 The low water content reduces moisture exchange between the shell and the contents, making HPMC an ideal choice for formulations containing moisture-sensitive and hygroscopic APIs.2

    2. Chemical Stability: HPMC is a much less chemically reactive polymer than gelatin.7 Most importantly, it is resistant to cross-linking.2 This ensures a stable and repeatable drug release profile throughout the shelf life of the product.

    3. Physical Stability: HPMC shells are much less sensitive to changes in temperature and humidity.2 They remain flexible even in low humidity conditions where gelatin becomes brittle.15

    4. Market Compatibility: As a plant-based product, HPMC meets all the requirements of consumers seeking vegan, vegetarian, Halal and Kosher products.2

     

    C. Pullulan: Properties and Uses (including Exceptional Oxygen Barrier)

     

    Pullulan is a natural, water-soluble polysaccharide.15 Unlike semi-synthetic HPMC, pullulan is produced by fermentation (e.g., tapioca starch) by the fungus Aureobasidium pullulans.9 Known under trade names such as Plantcaps®,9 it has one unique feature that sets it apart from the competition:

    • Exceptional Oxygen Barrier: Pullulan's most important advantage is its excellent oxygen barrier properties. Comparative analyses indicate that pullulan offers an oxygen barrier approximately nine times more effective than gelatin and as much as 250 times more effective than HPMC.13

    • Implications: This makes pullulan the material of choice for the most sensitive APIs, which are rapidly degraded by oxidative processes. Like HPMC, it is a plant-derived (natural) material with low moisture sensitivity.16

     

    D. Analysis of the Properties of Other Polymers

     

    Although gelatin, HPMC, and pullulan dominate the market, research and applications also include other polymers. These include starch capsules 8 and capsules made from polyvinyl alcohol (PVA). 8 PVA is a synthetic, water-soluble polymer known for non-technological applications (e.g., dishwasher capsules 18 ), but also has pharmaceutical potential.

    The rise in popularity of HPMC and pullulan is being driven by the powerful convergence of two seemingly unrelated trends. The first is consumer demand for "clean label," vegan, and natural products.2 The second, and much more important from a technological perspective, is the increasing complexity and sensitivity of new active ingredients (NMEs).2 Modern APIs are often highly hygroscopic2 or sensitive to oxidation. HPMC and pullulan, thanks to their properties (low moisture content, oxygen barrier), satisfy both these needs simultaneously, whereas gelatin is unable to meet either the market demands or the technical challenges posed by these new, sensitive molecules.

     

    Table 1: Comparison of key parameters of hard capsule shell materials



    Parameter

    Gelatine

    HPMC (Hypromellose)

    pullulan

    Origin

    Animal (collagen) 2

    Plant (semi-synthetic cellulose) 2

    Natural (starch fermentation) 9

    Equilibrium moisture content

    High (13–16%) 14

    Low (3–8%) 14

    Low 17

    Relative oxygen permeability

    Average 13

    High (low barrier) 13

    Very low (best barrier) 13

    Cross-linking Risk

    High 2

    Very low / None 2

    NO

    Key benefits

    Industry standard, low cost

    Stable, low moisture, vegan

    The best oxygen barrier, natural

    Main disadvantages

    Sensitivity to moisture, cross-linking, origin

    High oxygen permeability, higher cost

    Higher cost

     

    III. Empty Capsule Manufacturing Technology: Pin-Dipping Method

     

    The production process for empty hard capsules is a highly specialized operation that, at its core, represents a delicate balance between fluid dynamics, thermodynamics, and advanced materials science. The predominant method worldwide is pin-dipping.4

     

    A. Preparing the Dipping Solution

     

    The process begins with preparing a liquid polymer solution in which the molds will be immersed.19

    • For Gelatin: This solution is often a complex emulsion. In addition to gelatin itself, it may contain a number of excipients to optimize the process, such as diacetylated monoglycerides (as a lubricant), sodium lauryl sulfate (SLS) (as a surfactant to facilitate wetting of the molds), and colloidal silica (to reduce static electricity). All of this is intended to ensure ideal, uniform film distribution on the pin.19

    • For HPMC/Pullulan: These solutions have completely different rheology and properties. Preparation of an HPMC solution may require 70-95% water by weight and, depending on the formulation, the addition of special gelling agents, which are necessary for proper shell formation.20

     

    B. Detailed Description of the Production Cycle (Dipping, Drying, Stripping, Cutting)

     

    Immersion method 4 runs in the following cycle:

    1. Dipping: Thousands of precisely machined, polished metal molds (called "pins"), shaped to form the bodies and lids, are mounted on the bars. The bars are then immersed in a prepared polymer solution with precisely controlled temperature and viscosity.4

    2. Drying: Pins, coated with a thin layer of wet polymer film, are slowly withdrawn from the solution and transported through multi-level drying chambers. These chambers maintain precisely controlled temperature and humidity conditions, ensuring uniform solvent evaporation and film fixation.

    3. Stripping and Cutting: Once the target humidity is reached, the dried shells (bodies and lids) are automatically stripped (pulled) from the pins by mechanical "jaws", precisely cut to the required length, and then pre-assembled (body and lid) for ease of transport and packaging.

     

    C. Process Differences in Gelatin Capsule Production vs. HPMC

     

    A key technological aspect, often underestimated, is the fact that the production processes of gelatin and HPMC capsules are not identical and require fundamentally different equipment and process parameters.

    The difference is due to the gelation mechanism:

    • Gelatin forms a gel upon cooling (this is classic thermal gelation, as in Jell-O). So, the pins are often colder than the solution to "catch" the film.

    • HPMC (depending on the type) exhibits reverse thermal gelation, meaning it forms a gel when heated.20

    This means that the entire machine temperature profile—the temperature of the immersion solution, the temperature of the pins themselves, and the temperature profile of the drying chambers—must be radically different for HPMC than for gelatin. A gelatin capsule factory cannot simply "switch the solution" to HPMC and start production. This requires complete re-engineering, redesigning the machinery, and re-validating the entire process. This technological complexity is one factor explaining the higher cost of HPMC capsules and their slower adoption, despite their obvious formulation advantages.

    Moreover, innovations in the pin-dipping process itself enable the creation of capsules with advanced, built-in features. An example is ECDDT (Enteric Capsule Drug Delivery Technology), in which pharmaceutically approved enteric polymers (e.g., CAP) are incorporated directly into the HPMC dipping solution.4 This allows, using a conventional dipping process, the production of a coating that is intrinsically enteric—stable in acid and dissolving only at pH above 5.5.4

     

    IV. Pharmaceutical Formulation of Hard Capsule Fills



    A. The Role of Preformulation and Formulation Studies

     

    Developing an effective and stable capsule is a complex scientific process divided into two main phases.10

    1. Preformulation Phase: This phase involves in-depth physicochemical studies of the active ingredient (API) and potential excipients. This phase examines parameters such as solubility theory, crystallographic structure (polymorphism), hygroscopicity, particle size, and API stability under various conditions.10

    2. Formulation Phase: Based on preformulation data, technologists select the composition and manufacturing process to provide the active substance with "application characteristics." A key requirement is that the excipients used be compatible with the API and do not negatively impact its stability, pharmaceutical availability, or biological availability.10

     

    B. Fill Types: From Powders to Mini Tablets and Liquids

     

    The greatest advantage of hard capsules as a technology platform is their enormous versatility in terms of acceptable fill forms.11 Unlike tablets, which must be compressed, hard capsules can be filled:

    • Powders: Simple or complex mixtures of powders.1

    • Granulates: Used to improve flowability and homogeneity.1

    • Pellets: Small, spherical particles, often coated to modify release.6

    • Minitablets or Micro-Dragets: Very small tablets, often 1-3 mm in diameter.12

    • Liquids and Semi-Solids: Including oils, pastes, and hot-melt formulations.11

    • Combination Forms: It is possible to combine different forms, e.g. filling a capsule with a small tablet and powder 12 or with a liquid and pellets.26

     

    C. Categorization and Functions of Key Excipients (for solid formulations)

     

    Solid formulations (powders, granules) rarely consist solely of APIs. They require a set of excipients that provide the appropriate technological (enabling production) and biopharmaceutical (ensuring performance) properties.

    1. Diluents/Fillers: Necessary when the API dose is very small (e.g., micrograms or single milligrams). They increase the powder mass volume to a level that allows precise and repeatable capsule filling. Examples: lactose, mannitol, wheat starch, microcrystalline cellulose (MCC).23

    2. Glidants: Critical to the manufacturing process. Pharmaceutical powders often have poor flow properties. Glidants, added in small amounts (e.g., 0.1-1%), coat the API and filler particles, reducing friction between them and improving flow.28 This ensures uniform filling of the machine's hopper and dispensing disc. Examples: colloidal silicon dioxide (known as Aerosil®)27, talc.28

    3. Lubricants & Anti-adherents: These substances reduce friction and adhesion of powder to metal machine parts. In the context of encapsulation, their role is subtly different than in tableting. While in tablets, the main role of a lubricant is to reduce friction during high-pressure compression and ejection, in capsule machines (especially dosator-type machines), the anti-adherent function is crucial.27 They prevent powder from sticking to the tamping pins and the surface of the dispenser nozzle, which is crucial for a clean ejection of the formed powder plug.30 The most common example: magnesium stearate.29

    4. Disintegrants: The powder in a capsule, especially if tamper-filled (see Section VC), forms a compact "plug." For the API to be released quickly, this plug must disintegrate quickly upon contact with body fluid. Disintegrants swell in contact with water, mechanically "disintegrating" the formulation.28 Examples: starch, and currently primarily so-called superdisintegrants, such as croscarmellose sodium or crospovidone.28

     

    D. Challenges of Liquid and Semi-Solid Formulations (LFHC)

     

    Liquid-Filled Hard Capsules (LFHC) is an advanced technique but poses significant compatibility challenges, particularly with gelatin shells.14

    • Gelatin Limitations: The gelatin shell is sensitive to migration of plasticizers and water.

    • Hydrophilic liquid excipients are permitted only in limited quantities. The content of water and low molecular weight alcohols in the liquid filler should not exceed 10%.23

    • Hygroscopic substances such as glycerol or liquid polyethylene glycols (PEGs) are highly problematic.14 They can diffuse from the filler into the shell, causing it to soften unacceptably, or, conversely, "draw" water from the gelatin shell (which has 13-16% moisture), leading to its brittleness and cracking.14

    • Solutions: One approach is to adjust the formulation (e.g., by adding glycerol to the fill) to achieve thermodynamic equilibrium and prevent diffusion.23 However, a much more effective solution is to change the shell material. HPMC capsules, with their low moisture content (3-8%), are much less sensitive to hygroscopic fillers and are the platform of choice for such formulations.14

    • Process Requirements: Regardless of the coating, the liquid fill must have the appropriate viscosity to be precisely dispensed. The optimal viscosity range for modern fillers is 0.1–25 Pa s (i.e., 100–25000 cps).14

    The choice of excipients is therefore not an independent process but an interdependent system. Glidants (e.g., Aerosil) 28 are required because automatic filling machines 6 require excellent powder flow to ensure low weight variability. 32 In turn, the choice of liquid excipients (e.g., glycerol) 14 is directly limited or enabled by the choice of shell material (gelatin vs. HPMC).

     

    V. Industrial Capsule Filling and Closing Processes

     

    The transition from manual capsule filling to automated, industrial-scale production is the foundation of modern pharmacy. Modern encapsulation machines are highly complex mechatronic devices capable of delivering precise dosages at incredible speeds.

     

    A. Architecture and Components of Automatic Encapsulation Machines

     

    Modern production relies on fully automatic machines such as the NJP or CFK 33 series, which can fill thousands of capsules per minute5 while maintaining very high dose accuracy and repeatability.34

    The key components and workstations of such a machine include 6:

    • Capsule Hopper: Storage for empty, pre-assembled capsules.6

    • Orientation and Separation System: The first critical step. Capsules are drawn from the hopper and mechanically positioned in the correct orientation (cap side up). Next, the separation station, using negative pressure (vacuum), draws the cap away from the body.5

    • Rotary Turret: The heart of the machine. This is a rotating table equipped with segments with slots in which the open capsule bodies are placed. The turret rotates intermittently (or continuously in the highest-capacity machines), moving the bodies through the various workstations.

    • Powder Hopper: Storage for prepared formulation (powder, granules).

    • Dosing System: A key module responsible for precise filling of the cartridges. Its design varies drastically depending on the fill type (discussed below).6

    • Closing Station: After filling, the tower moves the body under the station where the lid (moved in parallel) is mechanically pushed back onto the body and locked (e.g. in a "snap" system).5

    • Ejection Station: The closed, filled capsules are ejected from the tower segments into a collection container or packaging line.

     

    B. Operational Sequence: From Orientation to Ejection of the Finished Capsule

     

    The filling process in an automatic machine takes place in the following sequence 5:

    1. Loading and Orientation: Empty capsules from hopper 33 are sorted and positioned in the nests.6

    2. Separation: A vacuum system separates the lid and body.5 The lids are lifted and held while the bodies remain in the lower segments of the tower.

    3. Filling (Dosing): The tower rotates, moving the open bodies under the dosing system, which precisely fills them with a measured dose of product.5

    4. Closing: The tower continues to rotate to the closing station where the lid is securely slid back onto the filled body.5

    5. Ejection: Finished, closed capsules are pushed out of the sockets.

     

    C. Dosing Technologies: Powders vs. Pellets

     

    The filling type 11 determines the type of dosing system that must be installed in the machine.6

    1. Tamping Systems (Tamping Pin / Dosator) for Powders:

    This is the most commonly used and most complex method of filling powders.6 This system consists of two key elements:

    • Dosing Disc: A thick, rotating disc with many precisely machined holes (slots).6

    • Tamping Pins: A set (usually 5-7) of punches that move in an up-down axis.6

    Process: The dosing disc rotates beneath the powder hopper. At successive positions, tamping pins enter the disc's holes, gradually tamping and compacting the powder.5 After several tamping operations (e.g., five), a precise, consistent powder plug is formed in the disc's cavity. In the final station, a special transfer pin pushes this plug from the disc directly into the empty capsule body waiting below.

    2. Volumetric Dosing Systems (for Pellets/Granulates):

    The process is fundamentally different. Pellets or granulates cannot be compacted because they would be destroyed, and their excellent flowability makes compaction unnecessary.6

    • For these molds, the machine does not use a dosing disc system or tamping pins in the sense of a tamping system.6

    • Instead, a simpler volume dosing system is used, which allows a precisely defined volume of free-flowing pellets to be poured directly into the capsule body.6

     

    D. Critical Process Parameter Analysis: Mass Variation Diagnostics

     

    The main technological and quality challenge in powder filling is achieving and maintaining low weight variation (WV) of capsules throughout a production run. High weight variation translates into inconsistent dosage and leads to batch rejection.

    Studies show that mass variability is strongly correlated with the rheological properties (flow) of the powder.32 Poor formulation flowability leads directly to higher fill variability.

    However, the analysis is more complex. Studies for ram systems 36 suggest that flowability alone may not be the only critical parameter, with powder compressibility (its ability to compact and form a cohesive plug) playing a key role. Other studies 30 point to two critical success factors: (1) maintaining a uniform powder bed in the hopper (related to flowability) and (2) smooth, clean ejection of the powder plug from the dispenser nozzle (related to compressibility and adhesion to metal).

    This distinction in dosing technologies (tamp vs. volumetric) 6 has profound formulation implications, particularly for low-dose/high-potency drugs.

    • Risk: Powder tamper filling relies on complex and difficult-to-control physics (flowability 32, density, compressibility 36). A small change in these parameters (e.g., a change in powder level in the hopper 35) results in a small change in plug weight. If the API dose is low (e.g., 1 mg in a 100 mg fill), this small change in plug weight can mean a huge percentage change in API dose (e.g., $\pm$20%), leading to a catastrophic failure of the Dosage Unit Uniformity test (see Section VII).

    • Strategy: Therefore, for such drugs, technologists often opt for a more complex formulation process—granulation or pelletization. Although this involves additional work during the R&D phase, it allows for de-risking the filling stage. Creating uniform pellets that encapsulate the API allows for a simpler, safer, and more reliable volumetric dosing system.6

     

    VI. Advanced Technologies and Specialized Applications of Hard Capsules

     

    The hard capsule has evolved from a simple powder container into a highly advanced drug delivery platform capable of realizing complex release profiles and protecting sensitive substances.

     

    A. Modified Release (MR) Capsules: The Role of Coated Pellets

     

    Hard capsules are an ideal carrier for multiple-unit pellet systems (MUPS).1 In this approach, the modified release function (e.g., prolonged, delayed) is not provided by the capsule shell itself. Instead, this function is "built into" the fill—usually pellets.37

    The technology involves coating cores (pellets) with polymer shells (e.g., hydrophobic, insoluble polymers such as ethylcellulose, or polymers soluble at a specific pH).37 The coating process takes place in specialized equipment, such as perforated drums or, which is preferred for small pellets, in fluidized bed coaters (e.g., in a Würster configuration, with a nozzle at the bottom of the chamber).37 These coated pellets are then precisely dosed into a standard hard capsule.

    The use of the MUPS system in a capsule is technologically safer and more reliable than a single modified-release tablet. A single MR tablet has a binary, all-or-none failure mode. If one of its coatings fails (e.g., breaks), the entire dose of drug is released immediately, a phenomenon known as "dose dumping" and can be hazardous to the patient. By dispersing the dose into hundreds of small pellets (37) or dozens of minitablets (24), the failure of the coating of a few individual units is statistically insignificant to the overall release profile. This ensures a highly reproducible, predictable, and safe pharmacokinetic profile in vivo.

     

    B. Enteric-Release Capsules: Two Methodologies

     

    The purpose of enteric-coated formulations is to protect the active ingredient from degradation in the acidic environment of the stomach or to protect the gastric mucosa from the irritating effects of the API.24 Release is intended to occur only at the higher pH of the small intestine. Hard capsule technology can achieve this goal in two different ways:

    1. Formulation Approach (Fill Coating):

    This is the traditional and most commonly used method. A standard hard capsule (e.g., gelatin) dissolves in the stomach. The capsule filling (pellets, granules, or minitablets) is coated with an enteric polymer (e.g., cellulose acetate phthalate, CAP) that is resistant to stomach acid.37

    A perfect example is the medicinal product Adifem (dimethyl fumarate).24 The product characteristics specify that it is a 24-ounce hard gelatin capsule containing mini-tablets.24 The capsule should be swallowed whole, as the enteric coating on the mini-tablets prevents irritation of the gastrointestinal tract.24

    2. Technological Approach (Enteric Coatings):

    This is a newer, more advanced technology that eliminates the need for coating the fill. Special capsules are used whose shell is intrinsically enteric.22 As described in Section III.C, this is achieved by incorporating enteric polymers (e.g., CAP) into the polymer mixture (e.g., HPMC) during the empty capsule manufacturing process (pin-dipping).4 Such capsules are acid-stable and dissolve only at pH > 5.5.4

    The development of enteric coatings 22 is a potentially disruptive technology. The traditional manufacturing process (approach 1) requires two separate, costly, and time-consuming production steps: (a) capsule filling and (b) coating the fill (e.g., in a fluidized bed 37). Integrating the enteric function into the coating 22 itself eliminates the entire coating step, which drastically simplifies production, validation, technology transfer, and "accelerates development time and reduces program risk." 22

     

    C. Liquid-Filled Hard Capsules (LFHC): Technology and Sealing (Banding) Techniques

     

    LFHC (Liquid-Filled Hard Capsules) technology is gaining importance as a key tool for solving bioavailability problems.

    • Advantages: Many new active pharmaceutical ingredients (APIs) are poorly soluble in water (BCS classification II or IV). Encapsulating such an API in a lipid-based formulation (oils, surfactants) in a capsule can dramatically improve its absorption and bioavailability.25 LFHCs also offer excellent protection for APIs sensitive to oxygen or moisture (because the API is dissolved in anhydrous oil)26 and require fewer excipients than tablets.26

    • Banding: A standard hard capsule ("snap-lock" type) is not airtight and is not suitable for long-term storage of liquids. The key supporting technology that makes this possible is banding (or sealing). After the capsule is filled with liquid, it is transported to a sealing machine. The process involves applying a thin strip (or band) of polymer solution (e.g., gelatin or HPMC) to the interface where the body and cap meet.40 Once dry, this strip forms a durable, airtight seal, preventing leaks while providing a visible tamper-evident seal.38

    LFHC technology is a direct competitor to soft capsules (Ang. softgels).11 However, it offers significant advantages:

    1. Material Flexibility: Softgels are almost exclusively gelatin-based (and contain plasticizers). LFHCs can use standard gelatin shells or, crucially, HPMC 14 shells, which are ideal for moisture-sensitive formulations that are impossible to encapsulate in softgelu.

    2. Formulation Flexibility: LFHCs allow for a combination of formulations. It is possible to fill a capsule simultaneously with a liquid (e.g., oil with API-1) and solid forms (e.g., pellets, minitablets with API-2).26 This is a unique capability that is not possessed by softgels, making LFHC a better platform for complex combination products.

    3. Cost Efficiency: Production softgels requires specialized, expensive machinery (e.g., rotary die method). LFHCs use standard encapsulators (with a liquid module) and add a banding step, which is often more flexible and less expensive.25

     

    D. Dry Powder Inhaler (DPI) Capsules: Requirements and Characteristics

     

    This is a highly specialized application of hard capsules, where they are not intended for swallowing, but for inhalation therapy.41

    • Characteristics: A capsule (usually gelatin or HPMC) contains a precisely measured, single, micronized dose of a drug in powder form (e.g., asthma or COPD medication).41

    • Directions for Use: The patient places the capsule into a dedicated inhaler (DPI – Dry Powder Inhaler). Upon use, the inhaler mechanically pierces or punctures the capsule shell. The force of the patient's inhalation is then used to cause the capsule to rapidly spin or vibrate, releasing (aerosolizing) the micronized powder, which is then delivered directly to the lungs along with the inhaled air.41

    • Function: The capsule acts as a precise, single-dose container, protecting the highly hygroscopic and sensitive powder from ambient moisture.41

     

    VII. Quality Assurance: Pharmacopoeial Research Methods

     

    Ensuring that each capsule produced is safe, effective and contains the declared dose requires a rigorous control regime quality (QC), described in pharmacopoeias (e.g. European Pharmacopoeia – Ph. Eur. or United States Pharmacopoeia – USP).

     

    A. Critical Functionality Research

     

    Two key tests assess how a drug formulation will behave after administration:

    1. Disintegration Time:

    • Test: Ph. Eur. 2.9.1.42

    • Objective: To determine whether capsules or tablets disintegrate into smaller fragments (that will pass through a sieve) within a specified time when placed in a liquid medium.43

    • Apparatus: The standard apparatus consists of a set of baskets (containing samples) that reciprocate in a beaker filled with a medium at a controlled temperature (usually 37°C).43

    • Specificity: For enteric-coated capsules (Section VI.B), the test is a two-step test: first, the samples must not disintegrate in simulated gastric fluid (0.1 M HCl), and then they must disintegrate rapidly when transferred to a buffer at intestinal pH.43

    2. Release of the Active Substance (Dissolution):

    • Test: Ph. Euro. 2.9.3/USP .42

    • Purpose: This is a key biopharmaceutical test. It does not test whether the capsule disintegrates, but rather how quickly and to what extent the active ingredient (API) is released (dissolved) from the drug formulation into the surrounding medium.

    • Apparatus: Two types of apparatus are most commonly used:

    • USP I Apparatus (Basket Method): The capsule is placed in a small, rotating basket immersed in a medium.46

    • USP II Apparatus (Paddle Method): The capsule (or tablet) falls freely to the bottom of the vessel and the medium is mixed by a rotating paddle.46

    • Result: These tests, often automated 46, allow sampling at different time points (e.g. every 5, 10, 15, 30 min), which allows the creation of a release profile (a graph of % API released versus time).

    These two tests are not the same and examine different aspects. Disintegration time 43 is a simple QC test for integrity. Release 46 defines the biopharmaceutical function of the product. This is particularly evident in advanced formulations (Section VI). A capsule with MR pellets must pass the disintegration test quickly (the capsule shell itself must disintegrate in the stomach), but must also demonstrate very slow release in the dissolution test (because the pellets control the release).

     

    B. The Evolution of Uniformity Testing: From Mass to UDU

     

    Ensuring that each capsule in a batch contains the same (narrowly defined) dose of API is a fundamental quality requirement. The methodology for testing this uniformity has undergone significant regulatory evolution.

    1. Historical Methods:

    Traditionally, pharmacopoeias have described two separate tests:

    • Ph. Eur. 2.9.5 (Uniformity of mass): Test for uniformity of mass.42 This test involved weighing 20 individual capsules. This test was based on the assumption that if the powder mixture is perfectly homogeneous, then uniform capsule mass implies uniform API content.

    • Ph. Eur. 2.9.6 (Uniformity of content): Testing for uniformity of content.42 Required when the above assumption could not be met (e.g., for low-dose drugs). Relied on costly and time-consuming chemical determination of the API content in 10 individual capsules.

    2. Current Standard: Harmonized Dosage Unit Uniformity Test (UDU)

    Currently, these two tests have been replaced and harmonized into a single, overarching statistical test 51:

    • Test: USP/Ph. Euro. 2.9.40 (Uniformity of Dosage Units).45

    The UDU test is structured as a single statistical procedure that can be performed using one of two analytical methods, depending on the risk associated with the product 53:

    • Method 1: Weight Variation (WV): This is the "easier" method (weighing only). The Pharmacopoeia allows its use only for low-risk products (e.g., hard capsules where the API dose is high, i.e., $\geq$ 25 mg and represents $\geq$ 25% of the total weight).

    • Method 2: Content Uniformity (CU): This is the more difficult method (requiring individual chemical analysis of 10, and potentially 30, capsules). It is absolutely required for all high-risk products—basically all low-dose medications.

    The acceptance criterion is based on the calculation of the so-called "Acceptance Value" (AV) based on the mean content, standard deviation and individual values ​​for 10 (or 30) units.52

    This regulatory evolution reflects a fundamental shift in the approach to quality – a shift to risk-based assessment. The old "Uniformity of Mass" test (2.9.5) 47 was dangerous for low-dose drugs because it relied on a false assumption of uniformity. In the case of powder segregation (flow problems 32 ), it is possible to produce a batch in which all capsules are of perfect weight, but some are sub-potent and others are toxic. The new UDU test (2.9.40) 53 addresses this risk by forcing manufacturers of high-risk (low-dose) drugs to use a more expensive but significantly safer method of testing for the actual API content (CU).

     

    Table 2: Summary of key pharmacopoeial studies for hard capsules



    Test

    Pharmacopoeial Number (Ph. Eur.)

    Apparatus Used

    Primary Research Objective

    When is Critical

    Time of Decay

    2.9.1 42

    Basket apparatus 43

    Checking whether a drug form disintegrates within a specified time.

    Always (for IR), crucial in 2 stages for enteral forms.43

    Active Substance Release

    2.9.3 42

    Basket apparatus (USP I) or paddle apparatus (USP II) 46

    Measuring the rate and degree of API dissolution. Crucial for biopharmaceuticals.

    Always; absolutely critical for MR and enteric forms.37

    Dosage Unit Uniformity (UDU)

    2.9.40 45

    Analytical balance (for WV) or HPLC/UV-Vis (for CU) 53

    Statistical assurance that each unit (capsule) contains the same dose of API.

    Always. The most important confirmation test quality filling process.

    Mass Uniformity

    2.9.5 42

    Analytical balance

    Historical method; now part of the UDU test (2.9.40) for low-risk products.

    as above

    Uniformity of Content

    2.9.6 42

    HPLC / UV-Vis

    Historical method; now part of the UDU test (2.9.40) required for high-risk products.53

    as above

     

    VIII. Conclusions and Directions for the Development of Hard Capsule Technology

     

    Despite its over 175-year history, hard capsule technology is evolving rapidly, adapting to new therapeutic and manufacturing challenges. The oral solid dosage form (OSD) market will remain dominant2, and hard capsules will continue to gain importance as the preferred platform for increasingly complex, potent, and sensitive APIs.2

     

    A. The Impact of 3D Printing on the Personalization of Capsule Doses

     

    One of the most promising directions of development in pharmacy is personalized medicine, including individual dose adjustments.57 3D printing technology (3D printing) is entering the pharmaceutical industry as a tool enabling the production of doses "on demand."58

    In the context of capsules, this technology is not (yet) used to print the shell itself, but rather to precisely print the fill. Studies demonstrate the use of 3D printing (e.g., FDM) to create mini-tablets with precisely tailored, individual doses (e.g., for pediatric use, where dosage is based on body weight).58

    In this model, a standard, empty hard capsule (e.g., HPMC) serves as an ideal, patient-acceptable carrier for delivering these personalized, 3D-printed mini-tablets.58 The capsule thus becomes a platform integrating advanced manufacturing (3D printing) with ease of administration.

     

    B. The Future: Capsule as an Integrated Delivery System

     

    The future of hard capsules is moving beyond a simple container and toward an integrative platform for personalized medicine and combination products. The ultimate capsule of the future could be a logical synthesis of all the advanced technologies discussed in this compendium.

    You can imagine a form of medicine that combines:

    1. A sheath made of Pullulan 13 to provide maximum oxygen barrier;

    2. Produced using ECDDT 22 technology to ensure that the coating is both internally enteric and protects the contents from stomach acid;

    3. Filled with LFHC 26 technology liquid formulation (e.g. oil) containing a first, poorly soluble active substance (API-1);

    4. Which simultaneously contains a second filling in the form of 3D printed 58 mini tablets with a personalized dose, containing a second, incompatible active substance (API-2).

    This design, although highly complex, is no longer a scientific fantasy but a logical extrapolation of existing and developing technologies.13 It demonstrates how the hard capsule has evolved from a simple, two-piece shell1 into a highly advanced, multi-chamber, multi-functional Drug Delivery System (DDS) capable of meeting the challenges of 21st century pharmacy.

    Works Cited

    Related Posts

    Scroll up